Developing a new class of engineered live bacterial therapeutics to treat human diseases

par Mark R. Charbonneau, Vincent M. Isabella, Ning Li, Caroline B. Kurtz
Publié 2020

Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria

par Mark R. Charbonneau, William S. Denney, Nicholas G. Horvath, Pasquale Cantarella, Mary J. Castillo, Marja K. Puurunen, Aoife M. Brennan
Publié 2021

Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip

par M. Tyler Nelson, Mark R. Charbonneau, Heidi G. Coia, Mary J. Castillo, Corey Holt, Eric S. Greenwood, Peter J. Robinson, Elaine A. Merrill, David Lubkowicz, Camilla A. Mauzy
Publié 2021